Myriad Genetics Celebrates One Million SneakPeek Results Shared With Expectant Parents
Portfolio Pulse from Benzinga Newsdesk
Myriad Genetics, Inc. (NASDAQ:MYGN) has announced that its SneakPeek Early Gender DNA Test has delivered results to one million consumers. The test, which can determine fetal sex as early as six weeks into pregnancy with 99% accuracy, can be taken at home or in a clinic. Myriad Genetics acquired Gateway Genomics, the developer of SneakPeek, in 2022, enhancing its suite of reproductive health testing solutions. The company also celebrated one million patients screened with its Prequel Noninvasive Prenatal Screen earlier this year.
November 20, 2023 | 9:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Myriad Genetics' SneakPeek test has reached a significant milestone, serving one million consumers. The acquisition of Gateway Genomics and the integration of SneakPeek into Myriad's product offerings may enhance the company's market position in reproductive health testing.
Reaching a milestone of one million consumers served by the SneakPeek test indicates strong market adoption and could positively influence investor sentiment. The acquisition of Gateway Genomics and the expansion of the reproductive health testing suite may lead to increased revenue streams and market share for Myriad Genetics, potentially boosting the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90